4.5 Review

Effects of Targeted Disruption of the Type 5 Adenylyl Cyclase Gene

Journal

JOURNAL OF PHARMACOLOGICAL SCIENCES
Volume 109, Issue 3, Pages 354-359

Publisher

JAPANESE PHARMACOLOGICAL SOC
DOI: 10.1254/jphs.08R26FM

Keywords

cardiac adenylyl cyclase; knockout mouse; autonomic nervous system; heart failure; longevity; cardiac disease

Funding

  1. National Institutes of Health [GM067773]
  2. American Heart Association [0020323U]
  3. Japanese Ministry of Education, Culture, Sports, Science, and Technology
  4. Japan Space Forum
  5. Kitsuen Kagaku Research Foundation
  6. Fukuda Foundation for Medical Technology
  7. Takeda Science Foundation
  8. Kimura Memorial Foundation/Pfizer Pharmaceuticals
  9. Yokohama Foundation for Advancement of Medical Science
  10. Yokohama City University, Japan [K19027]
  11. Mitsubishi Pharma Research Foundation
  12. Yokohama Academic Foundation
  13. Research for Promoting Technological Seeds
  14. NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067773] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Cyclic AMP (cAMP) is known to play a major role in regulating cardiac function. Difference in adenylyl cyclase (AC) isoforms is a potential mechanism by which the cAMP signal, a common second messenger signal, can be regulated in a tissue-specific manner. However, the physiological significance of expressing multiple AC isoforms in a tissue and how each specific isoform regulates the cAMP signal remains poorly understood. In a genetically engineered mouse model in which the expression of the type 5 AC is knocked out (AC5KO), we identified the attenuation of autonomic regulation and calcium-mediated inhibition of cardiac function. We also identified that disruption of type 5 AC preserves cardiac function in response to chronic pressure-overload and catecholamine stress, at least in part, through the inhibition of cardiac apoptosis, which plays a major role in the development of heart failure. The protection against both apoptosis and development of cardiac dysfunction induced by left ventricular pressure overload in AC5KO makes this molecule potentially important for developing future pharmacotherapy, where suppressing the activity of type 5 AC, and not the entire beta-adrenergic signaling (beta-AR) signaling pathway, may have an advantage over the current beta-AR-blockade therapy in the treatment of heart failure.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available